- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Medical Resources meets with NASDAQ
Imaging services provider Medical Resources of Hackensack, NJ, got at least a temporary reprieve from NASDAQ for its listing on the stock exchange, the company reported June 2. Medical Resources' NASDAQ listing was in jeopardy due to the company's
Imaging services provider Medical Resources of Hackensack, NJ, got at least a temporary reprieve from NASDAQ for its listing on the stock exchange, the company reported June 2. Medical Resources' NASDAQ listing was in jeopardy due to the company's inability to file its 10-K report with the Securities and Exchange Commission for 1997 financial results. The firm recently filed the report and will be able to maintain its listing, at least for the next several weeks.
NASDAQ set several conditions for the company's continued listing on the exchange. Medical Resources must file its quarterly 10-Q report for its first financial quarter (end-March) by June 12, and by July 24 must meet either NASDAQ's minimum net tangible assets requirement or an alternative requirement that its stock trade at a minimum bid of $5 a share. Medical Resources currently meets neither the tangible assets requirement nor the $5 a share requirement, although the company said it would implement a reverse stock split to meet the latter, if necessary.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
